CN105944088A - Composition for regulating ovarian function and application of composition - Google Patents
Composition for regulating ovarian function and application of composition Download PDFInfo
- Publication number
- CN105944088A CN105944088A CN201610493380.6A CN201610493380A CN105944088A CN 105944088 A CN105944088 A CN 105944088A CN 201610493380 A CN201610493380 A CN 201610493380A CN 105944088 A CN105944088 A CN 105944088A
- Authority
- CN
- China
- Prior art keywords
- ovarian
- ovarian function
- regulating
- radix
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002611 ovarian Effects 0.000 title claims abstract description 39
- 239000000203 mixture Substances 0.000 title claims abstract description 34
- 230000001105 regulatory effect Effects 0.000 title claims abstract description 27
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims abstract description 36
- 102000008186 Collagen Human genes 0.000 claims abstract description 25
- 108010035532 Collagen Proteins 0.000 claims abstract description 25
- 235000001667 Vitex agnus castus Nutrition 0.000 claims abstract description 18
- 244000063464 Vitex agnus-castus Species 0.000 claims abstract description 18
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 18
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims abstract description 18
- 235000009347 chasteberry Nutrition 0.000 claims abstract description 18
- 229960004488 linolenic acid Drugs 0.000 claims abstract description 18
- 239000011701 zinc Substances 0.000 claims abstract description 18
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 18
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 17
- 239000011777 magnesium Substances 0.000 claims abstract description 17
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims abstract description 11
- 230000006870 function Effects 0.000 claims description 44
- 230000033228 biological regulation Effects 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 14
- 230000036541 health Effects 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 5
- 235000013305 food Nutrition 0.000 claims description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims 1
- 239000005642 Oleic acid Substances 0.000 claims 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 27
- 229940088597 hormone Drugs 0.000 abstract description 11
- 239000005556 hormone Substances 0.000 abstract description 11
- 208000002500 Primary Ovarian Insufficiency Diseases 0.000 abstract description 8
- 206010036601 premature menopause Diseases 0.000 abstract description 8
- 208000017942 premature ovarian failure 1 Diseases 0.000 abstract description 8
- 208000024891 symptom Diseases 0.000 abstract description 8
- 208000005171 Dysmenorrhea Diseases 0.000 abstract description 4
- 206010013935 Dysmenorrhoea Diseases 0.000 abstract description 4
- 230000032683 aging Effects 0.000 abstract description 4
- 229920001436 collagen Polymers 0.000 abstract description 4
- 230000004060 metabolic process Effects 0.000 abstract description 4
- 201000004535 ovarian dysfunction Diseases 0.000 abstract description 4
- 206010036049 Polycystic ovaries Diseases 0.000 abstract description 3
- 201000010065 polycystic ovary syndrome Diseases 0.000 abstract description 3
- 239000003053 toxin Substances 0.000 abstract description 3
- 231100000765 toxin Toxicity 0.000 abstract description 3
- 108700012359 toxins Proteins 0.000 abstract description 3
- 230000002124 endocrine Effects 0.000 abstract description 2
- 210000004291 uterus Anatomy 0.000 abstract description 2
- 206010027304 Menopausal symptoms Diseases 0.000 abstract 1
- 208000037093 Menstruation Disturbances Diseases 0.000 abstract 1
- 206010027339 Menstruation irregular Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 235000001055 magnesium Nutrition 0.000 abstract 1
- 201000009240 nasopharyngitis Diseases 0.000 abstract 1
- 235000016709 nutrition Nutrition 0.000 abstract 1
- 239000013589 supplement Substances 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 235000016804 zinc Nutrition 0.000 abstract 1
- 239000000262 estrogen Substances 0.000 description 13
- 210000001672 ovary Anatomy 0.000 description 13
- 229940011871 estrogen Drugs 0.000 description 12
- 239000000284 extract Substances 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 210000000287 oocyte Anatomy 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 4
- 208000019255 Menstrual disease Diseases 0.000 description 4
- 230000003064 anti-oxidating effect Effects 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 230000002526 effect on cardiovascular system Effects 0.000 description 4
- 210000004696 endometrium Anatomy 0.000 description 4
- 229960003987 melatonin Drugs 0.000 description 4
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 4
- 230000009245 menopause Effects 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 3
- 241000218236 Cannabis Species 0.000 description 3
- 241000756943 Codonopsis Species 0.000 description 3
- 240000009087 Crescentia cujete Species 0.000 description 3
- 235000005983 Crescentia cujete Nutrition 0.000 description 3
- 102000015779 HDL Lipoproteins Human genes 0.000 description 3
- 108010010234 HDL Lipoproteins Proteins 0.000 description 3
- 102000007330 LDL Lipoproteins Human genes 0.000 description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 description 3
- 235000009797 Lagenaria vulgaris Nutrition 0.000 description 3
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000001771 cumulus cell Anatomy 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 230000035558 fertility Effects 0.000 description 3
- 230000003054 hormonal effect Effects 0.000 description 3
- 210000003016 hypothalamus Anatomy 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 235000020778 linoleic acid Nutrition 0.000 description 3
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 239000002858 neurotransmitter agent Substances 0.000 description 3
- 229960002748 norepinephrine Drugs 0.000 description 3
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 3
- 230000016087 ovulation Effects 0.000 description 3
- 239000000583 progesterone congener Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 239000009636 Huang Qi Substances 0.000 description 2
- 206010062767 Hypophysitis Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 235000009392 Vitis Nutrition 0.000 description 2
- 241000219095 Vitis Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000005515 coenzyme Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 210000004246 corpus luteum Anatomy 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 201000006828 endometrial hyperplasia Diseases 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 235000004626 essential fatty acids Nutrition 0.000 description 2
- 102000015694 estrogen receptors Human genes 0.000 description 2
- 108010038795 estrogen receptors Proteins 0.000 description 2
- 230000001076 estrogenic effect Effects 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 210000002149 gonad Anatomy 0.000 description 2
- 229940087603 grape seed extract Drugs 0.000 description 2
- 235000002532 grape seed extract Nutrition 0.000 description 2
- 238000001794 hormone therapy Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000005075 mammary gland Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000004681 ovum Anatomy 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 2
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 2
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 2
- 229960001327 pyridoxal phosphate Drugs 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 210000000801 secondary oocyte Anatomy 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 239000001717 vitis vinifera seed extract Substances 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- IQVQXVFMNOFTMU-FLIBITNWSA-N (Z)-ligustilide Chemical compound C1CC=CC2=C1C(=C/CCC)/OC2=O IQVQXVFMNOFTMU-FLIBITNWSA-N 0.000 description 1
- 241000906543 Actaea racemosa Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 108090000209 Carbonic anhydrases Proteins 0.000 description 1
- 102000003846 Carbonic anhydrases Human genes 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 206010054089 Depressive symptom Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- OVSQVDMCBVZWGM-SJWGPRHPSA-N Hyperin Natural products O[C@H]1[C@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-SJWGPRHPSA-N 0.000 description 1
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- 206010033165 Ovarian failure Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- IQVQXVFMNOFTMU-DHZHZOJOSA-N Z-ligustilide Natural products C1CC=CC2=C1C(=C/CCC)\OC2=O IQVQXVFMNOFTMU-DHZHZOJOSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000003679 aging effect Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000009188 angelicae sinensis extract Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 150000008331 benzenesulfonamides Chemical class 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000003969 blast cell Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 235000005301 cimicifuga racemosa Nutrition 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000005253 cladding Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000013530 defoamer Substances 0.000 description 1
- MGRRGKWPEVFJSH-UHFFFAOYSA-N dianthrone Natural products C12=CC=CC=C2C(=O)C2=CC=CC=C2C1=C1C2=CC=CC=C2C(=O)C2=CC=CC=C21 MGRRGKWPEVFJSH-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000013171 endarterectomy Methods 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 229940028334 follicle stimulating hormone Drugs 0.000 description 1
- 230000008217 follicular development Effects 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000000745 gonadal hormone Substances 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- IWBJJCOKGLUQIZ-HQKKAZOISA-N hyperforin Chemical compound OC1=C(CC=C(C)C)C(=O)[C@@]2(CC=C(C)C)C[C@H](CC=C(C)C)[C@](CCC=C(C)C)(C)[C@]1(C(=O)C(C)C)C2=O IWBJJCOKGLUQIZ-HQKKAZOISA-N 0.000 description 1
- MPGWGYQTRSNGDD-UHFFFAOYSA-N hypericin Chemical compound OC1=CC(O)=C(C2=O)C3=C1C1C(O)=CC(=O)C(C4=O)=C1C1=C3C3=C2C(O)=CC(C)=C3C2=C1C4=C(O)C=C2C MPGWGYQTRSNGDD-UHFFFAOYSA-N 0.000 description 1
- 229940005608 hypericin Drugs 0.000 description 1
- PHOKTTKFQUYZPI-UHFFFAOYSA-N hypericin Natural products Cc1cc(O)c2c3C(=O)C(=Cc4c(O)c5c(O)cc(O)c6c7C(=O)C(=Cc8c(C)c1c2c(c78)c(c34)c56)O)O PHOKTTKFQUYZPI-UHFFFAOYSA-N 0.000 description 1
- 238000009802 hysterectomy Methods 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 210000003552 inferior colliculi Anatomy 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000029860 luteolysis Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000008558 metabolic pathway by substance Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000008965 mitochondrial swelling Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000003557 neuropsychological effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 231100000539 ovarian failure Toxicity 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- SSKVDVBQSWQEGJ-UHFFFAOYSA-N pseudohypericin Natural products C12=C(O)C=C(O)C(C(C=3C(O)=CC(O)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 SSKVDVBQSWQEGJ-UHFFFAOYSA-N 0.000 description 1
- OVSQVDMCBVZWGM-DTGCRPNFSA-N quercetin 3-O-beta-D-galactopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-DTGCRPNFSA-N 0.000 description 1
- BBFYUPYFXSSMNV-UHFFFAOYSA-N quercetin-7-o-galactoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 BBFYUPYFXSSMNV-UHFFFAOYSA-N 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- -1 sphingomyelin Chemical class 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000003684 theca cell Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- 229930182493 triterpene saponin Natural products 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000005186 women's health Effects 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 238000004383 yellowing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/85—Verbenaceae (Verbena family)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a composition for regulating ovarian function. The composition comprises VB6, VC, VA, alpha-linolenic acid, linoleic acid, magnesium, zinc, vitex agnus-castus, radix angelicae sinensis, radix vernoniae asperae, herba hyperici perforati cum radice and collagen. The composition can remove human free radicals, regulate and balance human hormone levels, supplement nutritional elements and regulate human metabolism, so as to nourish female ovarian cells, regulate female endocrine balance and play a healthcare role in delaying the female aging; all active ingredients have a synergistic effect, can eliminate ovarian toxins, can significantly improve dysmenorrhea and uterus cold symptoms, is significant in ovarian function improvement effect, and can prevent and treat the menopausal syndrome, premature ovarian failure, polycystic ovaries and/or irregular menstruation and other ovarian hypofunction symptoms.
Description
Technical field
The present invention relates to the maintenance of ovary, particularly to compositions and application thereof for regulating ovarian function.
Background technology
Ovary is one of most important organ of human body women, is the place storing oocyte.The growth of follicle
It is an extremely complex process, is wrapped in by the cumulus cell of monolayer from the oocyte of resting state, from mother
Baby is formed for for 7 months, can static decades.And oocyte static in being wrapped in theca folliculi, as
Fruit is by Signal Regulation restoration ecosystem, and need just can grow up through 9 months slowly secondary oocyte.Now
Cladding cumulus cell parcel has been had to support outside oocyte in follicle.Hereafter 3 months secondary oocytes
Increased rapidly by secretion signal regulation and control such as cumulus cells, by last 15 days, the front first quarter moon of namely menstruation
Can maturation be mature follicle, and discharge oocyte, theca folliculi etc. and organize the formation of corpus luteum.In the moon
The front first quarter moon of warp, the Effect of estrogen secreted by follicle, endometrium constantly thickens, and rear first quarter moon corpus luteum is secreted
Estrogen and progestogen the most persistently make endometrial hyperplasia.Premenstrua, luteolysis, endometrium
Losing hormone support, at first 4～24 hours in the period, inner membrance blood vessel was spasmodic contraction, made inner membrance lack
Blood is downright bad, and diastole again after vasoconstriction, so that Rupture haemorrhag, forms scattered little hematoma at theca interna, makes
Endarterectomy and hemorrhage, be menstrual onset.So menoxenia, it is unbalance indirect of ovary ovulation function
Reaction.The height of the follicle stimulating hormone FSH of secretion is dlinial prediction and the important indicator judging ovarian function, FSH
More than 40IU/L menopause, FSH i.e. will menopause more than 20IU/L.Official holiday (the follicle of second day of normal person
Phase) FSH value 2-20IU/L.Premature ovarian failure refers to women menopause before 40 years old, does not has follicular development, promotees
Estrone FSH is more than 40IU/L, can cause losing fertility, and premature ovarian failure also affects ovarian secretion simultaneously
Progestogen, estrogen, affect the sexual function of women, also can directly result in the aging of women.The most
Ovary through there being research young makes menopausal women recover again physiological period after transplanting, it is seen that the function of ovary
Health and younger state for woman have the biggest relation.Climacteric syndrome is because hypophysis inferior colliculus
After the fertility axle positive feedback of brain and ovary stops, there is no hormone secretion, cause official holiday to stop.Health hormone
After reducing rapidly, sexual life is impacted, and emotion is the most out of control, and health many organ cells have hormone receptor,
After gonadal hormone declines, cardiovascular Aging is accelerated, and easily produces osteoporosis.The ovulation of ovary and secreting hormone
Function by the regulation and control of pituitary-hypothalamic-hypothalamic pituitary ovarium axis (fertility axle).Hypophysis acts on hypothalamus, hypothalamus
Acting on ovary, the hormone of ovary and pendant secretion can act on again hypothalamus in turn.Between three
There is positive negative action, any link functional disorder causes the female incretion system of various hormone and regulates different
Often, the exception of ovulation is finally caused.But, the treatment of premature ovarian failure in the prior art only has hormonal supplementation,
Cure the symptoms, not the disease.So far, still the most effective remedy measures recovers or protection ovarian function.Mesh
Before, the main method for the treatment of premature ovarian failure is by hormone therapy, and patient often needs estrogen, or female, pregnant
Hormone therapy.Although this method can eliminate climacteric syndrome, but after drug withdrawal, majority are easily recurred,
And the side effect of hormone brings the biggest burden to too patient's body and mind.Recently American Women health association
Clinical research find, Hormone Replacement Therapy (HRT) although reducing the danger of osteoporosis and fracture, but
But the incidence probability of breast carcinoma, carcinoma of endometrium and cardiovascular, apoplexy is added.As can be seen here, hormone
Alternative medicine can not be referred to as one safely and effectively Therapeutic Method.
Summary of the invention
In view of this, it is an object of the invention to provide a kind of compositions for regulating ovarian function and answer
With, by removing human free radical and adjustment human hormone's level, extra-nutrition element regulation human body generation
Thank, thus nourish women gonad cell, regulation female incretion balance, plays the health care of delaying female aging
Effect, has synergism between each crude drug, it is possible to gets rid of ovary toxin, makes dysmenorrhea, cold womb symptom bright
Aobvious improving, it is obvious that ovarian function improves effect, it is possible to prevent and treat climacteric syndrome, premature ovarian failure,
The ovarian hypofunction symptom such as polycystic ovary and/or menoxenia.
The compositions for regulating ovarian function of the present invention, including following components: 50～100mg VB6,
1～2g VC, 1500～2000ugVA, 2～4g alpha-linolenic acid, 4～8g linoleic acid, 350～700mg magnesium,
15～25mg zinc, 20～30mg Vitex agnus-castus Linn., 20～30g Radix Angelicae Sinensis, 40～80mg Radix vernoniae asperae, 500～800mg
Herba Hyperici perforati, 3～6g collagen protein；
Further, including following components:
60～90mg VB6,1～2g VC, 1700～2000ugVA, 2～4g alpha-linolenic acid, 4～8g Asia oil
Acid, 400～650mg magnesium, 18～25mg zinc, 24～30mg Vitex agnus-castus Linn., 24～30g Radix Angelicae Sinensis, 50～
70mg Radix vernoniae asperae, 600～800mg Herba Hyperici perforati, 3～6g collagen protein；
Further, including following components:
70mg VB6,1.5g VC, 1500～2000ugVA, 3g alpha-linolenic acid, 6g linoleic acid, 500mg
Magnesium, 20mg zinc, 26mg Vitex agnus-castus Linn., 26g Radix Angelicae Sinensis, 60mg Radix vernoniae asperae, 700mg Herba Hyperici perforati, 5g
Collagen protein.
The compositions for regulating ovarian function of the present invention, can add medicine, health care conduct and learning, bromatology
On the carrier that can accept make preparation.Such as can add the melatonin of 0.2-0.5g, as potent antioxygen
Premature ovarian failure is played obvious inhibitory action by agent and free radical scavenger, improves ovarian function, improves ovum
Blast cell quality；Also can add Semen Vitis viniferae extract, calabash seed extract, Fructus Cannabis extract for increasing
Adding immunity, endocrine regulation, improve the activity of ovarian function cell, its consumption is 0.03-0.06g.
The present invention is used for the compositions regulating ovarian function in preparation for regulating the medicine of ovarian function, guarantor
Application on strong product, food.
Beneficial effects of the present invention: compositions and the application thereof for regulating ovarian function of the present invention, passes through
Remove human free radical and adjustment human hormone's level, extra-nutrition element regulation body metabolism, thus
Nourish women gonad cell, regulation female incretion balance, play the health-care effect of delaying female aging, respectively
There is synergism, it is possible to get rid of ovary toxin, make dysmenorrhea, cold womb symptom be obviously improved between crude drug,
It is obvious that ovarian function improves effect, it is possible to prevents and treat climacteric syndrome, premature ovarian failure, polycystic ovary
And/or the ovarian hypofunction symptom such as menoxenia.
Magnesium: as the macroelement of human body, is the activator of multiple enzyme, participates in more than 300 kind enzymatic reactions,
Synthesis and decomposition, energy metabolism, nerve, the excitement of muscle to nutrient (sugar, fat, protein)
Property all has regulation effect.
Collagen protein: be to support and the key protein of protection connective tissue, collagen protein and hydrolysate thereof with
The structure of application on human skin collagen is similar, and the compatibility is good.Collagen protein contains 18 kinds of aminoacid, can give skin required
Nutrient, be that collagen protein activity in skin is strengthened.The affinity of collagen protein and surrounding tissue is fine,
Thus there is the effect of repair tissue.Containing substantial amounts of hydrophilic group in collagen molecules, it is allowed to have good
Moisture-keeping efficacy, it is possible to reach the purpose keeping skin moist.Collagen protein has regulation and stablizes skin
The effect of PH.Additionally, also have the effect promoting wound healing, radiating, strengthen skeletonization.
Vitex agnus-castus Linn.: main containing casting off a skin the biochemical compositions such as black ketone, terpenoid, flavonoid and lignanoids.
Pharmaceutical research show its have analgesia, antiinflammatory, antibacterial, antitumor, suppression lymphocyte and hormonal regulation,
Antioxidation isoreactivity, its mechanism is probably Vitex agnus-castus Linn. extract and can be combined with estrogen receptor competitively,
Regulate internal estrogen level, thus regulate women disturbance of circulation, be used clinically for treating climacteric comprehensive
Levy.
Radix Angelicae Sinensis: sweet in the mouth, pungent, warm in nature, have enrich blood, invigorate blood circulation, regulating menstruation, analgesia, effect of intestine moistening.Its institute
Matters of containing biological activities mainly has the compositions such as volatile oil, ferulic acid, Ligustilide, polysaccharide, have antioxidation,
The function such as defying age, anti-inflammatory, antibacterial, antithrombotic, anticancer, resisting fatigue, regulation immunity.Pharmacological research shows
Showing, Radix Angelicae Sinensis extract has the VEGF (VEGF) of promotion ovary and reaches to protect ovary
Function, and also play the effect promoting endometrial hyperplasia.Additionally, the volatile oil in Radix Angelicae Sinensis leads to
Cross the generation of suppression Intrauterine Inflammation factor PGE and improve the level of internal progestogen, thus playing anti-dysmenorrhea
Effect and the effect of inflammation of uterus.
Radix vernoniae asperae: be mainly composed of triterpene saponin, its major function is to directly act on central nervous system
System, has regulation effect to neurotransmitter (5-hydroxy tryptamine, dopamine, norepinephrine), thus improves low
Tidal fever with perspiration that estrogen causes and neuropsychological symptom.Radix vernoniae asperae can also pass through Mediated by Estrogen Receptor,
With estrogen synergism, but there is tissue selectivity, present estrogen-like effects at skeleton, i.e. suppress bone
The loss of matter, increases bone density；Estrogenic antagonist is presented in mammary gland, endometrium.And Radix vernoniae asperae antithetical phrase
Endometrium, mammary gland, thrombin and liver enzyme do not affect, and Black Cohosh P.E is to serum sex hormone level not
Produce impact.
Herba Hyperici perforati (Herba Hyperici perforati): Herba Hyperici perforati contains abundant flavonoid (hyperin), a benzenesulfonamide derivative
The bioactive ingredients such as thing (hyperforine), naphthalene a pair of horses going side by side dianthrone class (hypericin), wherein Radix Hyperici Monogyni (Herba Hyperici Monogyni)
Element can be effectively improved Women’s climacteric or enclose the depressive symptom in menstrual period, and its mechanism of action may and stop between synapse
Gap neurotransmitter serotonin, dopamine, norepinephrine, GABA are relevant with glutamic acid reuptake.
VB6: using its activity form PLP (pyridoxal 5-phosphate) as the coenzyme of many enzymes, participation neurotransmitter,
The metabolism of carbohydrate, sphingomyelin, heme, fat and nucleic acid, simultaneously participates in all ammonia
Base acid metabolic.In addition VB6 and immune system, nervous system are the most closely related.
VA:VA is a kind of coenzyme of regulation glycoprotein synthesis, and the cell membrane of epithelial cell is risen Stabilization,
The form that can maintain epithelial cell completely perfects with function, cardiovascular and cerebrovascular vessel is had protective effect, plays antioxygen
Change effect；Also it is the substrate constituting visual impression stimulative substance, plays an important role to maintaining normal visual acuity；VA also joins
With cell DNA and the synthesis of RNA, cell differentiation and tissue renewal are had a certain impact, also there is raising
The effect of Abwehrkraft des Koepers.
VC has antioxidation, or strong reductant as electron donor, and it is as internal maintenance hydroxylase activity
Necessary cofactor, participates in synthesis and the metabolism of internal many important substance, such as collagen protein, 5-hydroxyl
Tryptamines, norepinephrine etc., additionally have removing toxic substances, the effect of raising Abwehrkraft des Koepers.
Zinc: be constituent and (or) the agonist of human body many important enzymes, such as archaeal dna polymerase, alkalescence
Phosphatase, carbonic anhydrase, lactic acid dehydrogenase, superoxide dismutase etc., participate in internal many kinds of substance metabolism,
Immunomodulating, antioxidation, anti-apoptotic and antiinflammatory play an important role.Additionally, zinc also participates in islets of langerhans
Element synthesis.
Alpha-linolenic acid: as the essential fatty acid of human body, is the important component part of phospholipid, maintains cell
Structural integrity and function are normal, and the normal function maintaining brain and neurocyte is had important function, in addition
There is promotion plasma low density lipoprotein (LDL) convert to high density lipoprotein (HDL), reduce LDL, rise
The effect of high HDL, and then reduce blood fat, atherosclerosis, cardiovascular and cerebrovascular disease are had protective effect；
Alpha-linolenic acid and metabolite EPA and DHA thereof can suppress T cell and other cells to produce pro-inflammatory cells
The factor such as IL-1, IL-2, IL-6 and TNF-a etc., therefore have anti-inflammatory properties；Additionally have antitumor,
Improve the effect of immunity.
Linoleic acid: as the essential fatty acid of human body, relevant with the spermiogenesis tail of animal, research finds, as
Really meals medium-term and long-term shortage linoleic acid, animal experiment proves to may occur in which that infertility, fertilization process also occur obstacle.
There is the effect reducing cholesterol；Produced by suppression adhesion molecule, chemotactic factor and cytokine etc., tool
There is the effect of antiinflammatory；And these factors also assist in the key molecule of Atherosclerosis, therefore, also have
Protected cardiovascular disease effect.Improve insulin sensitivity, the suppression propagation of pancreatic cancer cell, migration and
Promote its apoptosis, play antitumaous effect.In addition linoleic acid is histiocytic constituent, particularly participates in
Mitochondrion and the synthesis of cell membrane phospholipid.To maintaining skin and nerve, the Growth and Differentiation of brain cell, there is weight
Act on.As linoleic acid lack may result in mitochondrial swelling, membrane structure, changing function, membrane permeability,
Fragility increases, and causes skin eczema occur.
Detailed description of the invention
Embodiment one
The compositions for regulating ovarian function of the present embodiment, including following components: 50～100mg VB6,
1～2g VC, 1500～2000ugVA, 2～4g alpha-linolenic acid, 4～8g linoleic acid, 350～700mg magnesium,
15～25mg zinc, 20～30mg Vitex agnus-castus Linn., 20～30g Radix Angelicae Sinensis, 40～80mg Radix vernoniae asperae, 500～800mg
Herba Hyperici perforati, 3～6g collagen protein.
Embodiment two
Including following components: 50～100mg VB6,1～2g VC, 1500～2000ugVA, 2～4g α-
Linolenic acid, 4～8g linoleic acid, 350～700mg magnesium, 15～25mg zinc, 20～30mg Vitex agnus-castus Linn.,
20～30g Radix Angelicae Sinensis, 40～80mg Radix vernoniae asperae, 500～800mg Herba Hyperici perforati, 3～6g collagen protein.
Embodiment three
The compositions for regulating ovarian function of the present embodiment, including following components:
60～90mg VB6,1～2g VC, 1700～2000ugVA, 2～4g alpha-linolenic acid, 4～8g Asia oil
Acid, 400～650mg magnesium, 18～25mg zinc, 24～30mg Vitex agnus-castus Linn., 24～30g Radix Angelicae Sinensis, 50～
70mg Radix vernoniae asperae, 600～800mg Herba Hyperici perforati, 3～6g collagen protein.
Embodiment four
The compositions for regulating ovarian function of the present embodiment, including following components:
60～90mg VB6,1～2g VC, 1700～2000ugVA, 2～4g alpha-linolenic acid, 4～8g Asia oil
Acid, 400～650mg magnesium, 18～25mg zinc, 24～30mg Vitex agnus-castus Linn., 24～30g Radix Angelicae Sinensis, 50～
70mg Radix vernoniae asperae, 600～800mg Herba Hyperici perforati, 3～6g collagen protein.
Embodiment five
The compositions for regulating ovarian function of the present embodiment, including following components:
60～90mg VB6,1～2g VC, 1700～2000ugVA, 2～4g alpha-linolenic acid, 4～8g Asia oil
Acid, 400～650mg magnesium, 18～25mg zinc, 24～30mg Vitex agnus-castus Linn., 24～30g Radix Angelicae Sinensis, 50～
70mg Radix vernoniae asperae, 600～800mg Herba Hyperici perforati, 3～6g collagen protein.
Embodiment six
The compositions for regulating ovarian function of the present embodiment, including following components:
70mg VB6,1.5g VC, 1500～2000ugVA, 3g alpha-linolenic acid, 6g linoleic acid, 500mg
Magnesium, 20mg zinc, 26mg Vitex agnus-castus Linn., 26g Radix Angelicae Sinensis, 60mg Radix vernoniae asperae, 700mg Herba Hyperici perforati, 5g
Collagen protein.
Embodiment seven
Including following components: 60mg VB6,10g VC, 1800ugVA, 3g alpha-linolenic acid, 6g linoleic acid,
500mg magnesium, 20mg zinc, 25mg Vitex agnus-castus Linn., 25g Radix Angelicae Sinensis, 60mg Radix vernoniae asperae, 700mg pass through leaf even
Stick up, the Qi-tonifying drug Radix Codonopsis of 4g collagen protein, 0.2g, the melatonin of 0.3g, 0.04g Semen Vitis viniferae extract.
Embodiment eight
Including following components: 50mg VB6,2g VC, 1500ugVA, 4g alpha-linolenic acid, 4g linoleic acid,
700mg magnesium, 15mg zinc, 30mg Vitex agnus-castus Linn., 20g Radix Angelicae Sinensis, 80mg Radix vernoniae asperae, 500mg pass through leaf even
Stick up, the Qi-tonifying drug Radix Codonopsis of 6g collagen protein, 0.1g, 0.3g Radix Astragali, the melatonin of 0.2g, 0.06g Portugal
Grape seed extract, 0.03g calabash seed extract, 0.06g Fructus Cannabis extract.
Embodiment nine
Including following components: 100mg VB6,1g VC, 2000ugVA, 2g alpha-linolenic acid, 8g linoleic acid,
350mg magnesium, 25mg zinc, 20mg Vitex agnus-castus Linn., 30g Radix Angelicae Sinensis, 40mg Radix vernoniae asperae, 800mg pass through leaf even
Stick up, the Qi-tonifying drug Radix Codonopsis of 3g collagen protein, 0.3g, 0.1g Radix Astragali, the melatonin of 0.5g, 0.03g Portugal
Grape seed extract, 0.06g calabash seed extract, 0.03g Fructus Cannabis extract.
The compositions being used for regulating ovarian function of above-described embodiment is added medical science or bromatology or health product
The carrier that can accept on makes preparation, and any adjuvant that can use by adding this area is prepared as fitting
The dosage form closed.Described adjuvant includes but not limited to disintegrating agent, filler, lubricant, wetting agent, solubilising
Agent, cosolvent, emulsifying agent, coloring agent, adhesive, osmotic pressure, regulator, stabilizer, fluidizer,
Correctives, preservative, suspending agent, coating material, aromatic, anti stickness agent, antioxidant, antioxygen potentiation
Agent, intercalating agent, penetration enhancer, pH adjusting agent, plasticizer, surfactant, foaming agent, defoamer,
Thickening agent, inclusion agents, wetting agent, absorbent, diluent, flocculant and deflocculant, filter aid etc..
The compositions regulating ovarian function will be used at preparation the regulation food of ovarian function, health product, medicine
In application.
Experimental example:
For regulating the compositions of ovarian function to E2, FSH hormonal readiness change impact in mice serum
Laboratory animal: Healthy female kunming mice, 8 weeks ages of Mus, 23 degree of-25 degree of raising temperature, phase
To humidity 50-60%, ad lib, water inlet, illumination every day 12 hours, carry out adaptability raising.
Test method: Animal adaptability is tested after raising one week, is divided into 7 groups, often group 10,
It is respectively blank group, embodiment 1 group, embodiment 2 groups, embodiment 3 groups.
The body weight of mice about 30g, according to people and Mouse Weight ratio, designs dosage.
Estrogen assay method: use double antibody two step sandwich ELISA method (ELISA).By standard
Product, sample to be tested join and are coated mouse oestrogen (E2) monoclonal antibody transparent enzyme mark in advance and are coated plate
In, after incubation enough time, washing removes unconjugated composition, adds enzyme mark working solution, incubation foot
After the enough time, washing removes unconjugated composition.Being sequentially added into substrate A, B, substrate (TMB) is in Radix Cochleariae officinalis mistake
It is converted into blue product under oxide enzyme (HRP) catalysis, yellowing under the action of an acid, the depth of color
It is proportionate with sample small mouse estrogen (E2) concentration, under 450nm wavelength, measures OD value, root
According to the OD value of standard substance and sample, calculate sample small mouse estrogen (E2) content.
Experimental result is as follows:
Test result indicate that, the laboratory animal using compositions 1-3 embodiment for regulating ovarian function is equal
Significantly improve compared to blank group, the estrogen content of laboratory animal, improve significant difference, the present invention's
Vitamin-medicine composition can improve estrogen secretion.
Case:
Case 1
Lee XX, 45 years old, patients of the hysterectomy, after entering into the climacteric period, ovarian failure was serious, still occurs
Serious hectic fever and irritated symptom, affect work.Take the group for regulating ovarian function of embodiment 1
After compound one month, remission, FSH is reduced to 50IU/L by 87IU/L.This case shows the present invention's
Vitamin-medicine composition is capable of ovarian function maintenance, treatment climacteric syndrome.
Case 2
X, 37 years old, menopause 2 years, take the compositions for regulating ovarian function of embodiment 1
3 months, FSH was reduced to 28IU/L from 120IU/L, recovered official holiday.After drug withdrawal 3 months, FSH increases to again
48IU/L, menolipsis.This case shows that the vitamin-medicine composition of the present invention can treat menoxenia and ovum
Nest senilism.
Finally illustrate, above example only in order to technical scheme to be described and unrestricted, although
With reference to preferred embodiment, the present invention is described in detail, it will be understood by those within the art that,
Technical scheme can be modified or equivalent, without deviating from technical solution of the present invention
Objective and scope, it all should be contained in the middle of scope of the presently claimed invention.
Claims (5)
1. one kind for regulating the compositions of ovarian function, it is characterised in that: include following components:
50～100mg VB6,1～2g VC, 1500～2000ugVA, 2～4g alpha-linolenic acid, 4～8g are sub-
Oleic acid, 350～700mg magnesium, 15～25mg zinc, 20～30mg Vitex agnus-castus Linn., 20～30g Radix Angelicae Sinensis, 40～
80mg Radix vernoniae asperae, 500～800mg Herba Hyperici perforati, 3～6g collagen protein.
Compositions for regulating ovarian function the most according to claim 1, it is characterised in that: include
Following components:
60～90mg VB6,1～2g VC, 1700～2000ugVA, 2～4g alpha-linolenic acid, 4～8g Asia oil
Acid, 400～650mg magnesium, 18～25mg zinc, 24～30mg Vitex agnus-castus Linn., 24～30g Radix Angelicae Sinensis, 50～
70mg Radix vernoniae asperae, 600～800mg Herba Hyperici perforati, 3～6g collagen protein.
Compositions for regulating ovarian function the most according to claim 2, it is characterised in that: include
Following components:
70mg VB6,1.5g VC, 1500～2000ugVA, 3g alpha-linolenic acid, 6g linoleic acid, 500mg
Magnesium, 20mg zinc, 26mg Vitex agnus-castus Linn., 26g Radix Angelicae Sinensis, 60mg Radix vernoniae asperae, 700mg Herba Hyperici perforati, 5g
Collagen protein.
4. according to the compositions for regulating ovarian function described in claim 1-3 any claim, its
It is characterised by: the carrier that can accept in medicine, health care conduct and learning, bromatology can be added and make preparation.
5. according to the compositions for regulating ovarian function described in claim 1-3 any claim in system
It is ready for use on the application on the regulation medicine of ovarian function, health product, food.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610493380.6A CN105944088A (en) | 2016-06-29 | 2016-06-29 | Composition for regulating ovarian function and application of composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610493380.6A CN105944088A (en) | 2016-06-29 | 2016-06-29 | Composition for regulating ovarian function and application of composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105944088A true CN105944088A (en) | 2016-09-21 |
Family
ID=56901711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610493380.6A Pending CN105944088A (en) | 2016-06-29 | 2016-06-29 | Composition for regulating ovarian function and application of composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105944088A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107348379A (en) * | 2017-07-05 | 2017-11-17 | 上海拜汶医药科技有限公司 | A kind of composite nutrient protected and improve women ovarian function |
| CN109198619A (en) * | 2018-09-27 | 2019-01-15 | 北京斯利安药业有限公司 | A kind of composition and its application with raising fecundity effect |
| CN111513269A (en) * | 2020-04-16 | 2020-08-11 | 自然资源部第三海洋研究所 | Abalone viscera extract and application thereof |
| CN113730558A (en) * | 2021-09-09 | 2021-12-03 | 广东圆康再生医学科技开发有限公司 | Ovarian oocyte repair composition and preparation method thereof |
| CN114848636A (en) * | 2022-06-15 | 2022-08-05 | 宁夏医科大学 | Medicine for treating premature ovarian failure induced by overactivation of primordial follicles caused by chemotherapy |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1391464A (en) * | 1999-09-30 | 2003-01-15 | 药物技术公司 | Formulation for menopausal women |
| CN1728989A (en) * | 2002-02-15 | 2006-02-01 | 白奥诺里卡制药股份公司 | Use of extracts containing phytoestrogen selectively modulating estrogen-receptor-beta. |
| CN101868243A (en) * | 2007-11-21 | 2010-10-20 | 客乐谐制药株式会社 | Aromatase inhibitor |
| CN103082283A (en) * | 2012-11-12 | 2013-05-08 | 王磊 | Seaweed essential oil soft capsule and preparation method thereof |
| CN104042881A (en) * | 2014-07-10 | 2014-09-17 | 上海泰坤堂中医医院有限公司 | Compositions used for regulating functions of ovary |
| CN104288432A (en) * | 2014-09-17 | 2015-01-21 | 苟春虎 | Female Viagra capsule |
-
2016
- 2016-06-29 CN CN201610493380.6A patent/CN105944088A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1391464A (en) * | 1999-09-30 | 2003-01-15 | 药物技术公司 | Formulation for menopausal women |
| CN1728989A (en) * | 2002-02-15 | 2006-02-01 | 白奥诺里卡制药股份公司 | Use of extracts containing phytoestrogen selectively modulating estrogen-receptor-beta. |
| CN101868243A (en) * | 2007-11-21 | 2010-10-20 | 客乐谐制药株式会社 | Aromatase inhibitor |
| CN103082283A (en) * | 2012-11-12 | 2013-05-08 | 王磊 | Seaweed essential oil soft capsule and preparation method thereof |
| CN104042881A (en) * | 2014-07-10 | 2014-09-17 | 上海泰坤堂中医医院有限公司 | Compositions used for regulating functions of ovary |
| CN104288432A (en) * | 2014-09-17 | 2015-01-21 | 苟春虎 | Female Viagra capsule |
Non-Patent Citations (7)
| Title |
|---|
| 刘妍如: "更年期综合征及贯叶连翘治疗机制的代谢组学研究", 《中国博士学位论文全文数据库（电子期刊）医药卫生科技辑》 * |
| 叶兆伟: "《中药药理学》", 31 August 2015, 重庆大学出版社 * |
| 山东省卫生厅: "《乡村医生中医药知识与技能培训教材——实用中药方剂学》", 31 December 2006, 山东科学技术出版社 * |
| 张志雄: "《生理学》", 31 August 2011, 上海科学技术出版社 * |
| 新疆维吾尔自治区卫生厅: "《维吾尔药材标准上册》", 31 August 1993, 新疆科技卫生出版社 * |
| 蒙娜丽莎•舒尔茨: "《新女性大脑》", 31 January 2011, 上海科学技术文献出版社 * |
| 贾敏如: "《国际传统药物和天然药物》", 31 October 2006, 中国中医药出版社 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107348379A (en) * | 2017-07-05 | 2017-11-17 | 上海拜汶医药科技有限公司 | A kind of composite nutrient protected and improve women ovarian function |
| CN109198619A (en) * | 2018-09-27 | 2019-01-15 | 北京斯利安药业有限公司 | A kind of composition and its application with raising fecundity effect |
| CN111513269A (en) * | 2020-04-16 | 2020-08-11 | 自然资源部第三海洋研究所 | Abalone viscera extract and application thereof |
| CN111513269B (en) * | 2020-04-16 | 2022-07-19 | 自然资源部第三海洋研究所 | Abalone viscera extract and application thereof |
| CN113730558A (en) * | 2021-09-09 | 2021-12-03 | 广东圆康再生医学科技开发有限公司 | Ovarian oocyte repair composition and preparation method thereof |
| CN114848636A (en) * | 2022-06-15 | 2022-08-05 | 宁夏医科大学 | Medicine for treating premature ovarian failure induced by overactivation of primordial follicles caused by chemotherapy |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105944088A (en) | Composition for regulating ovarian function and application of composition | |
| NS et al. | Effects of Gelam honey on sperm quality and testis of rat | |
| US10624942B2 (en) | Composition for amelioration of peri- and post-menopausal symptoms and a process for producing the same | |
| Manouchehri et al. | Polycystic ovaries and herbal remedies: A systematic review | |
| CN1970007A (en) | Capsule for improving sexual function for men | |
| Rakuambo et al. | In vitro effect of medicinal plants used to treat erectile dysfunction on smooth muscle relaxation and human sperm | |
| Rohdewald | Update on the clinical pharmacology of Pycnogenol (R) | |
| CN113398078B (en) | Granular traditional Chinese medicine for improving ovarian reserve function and preparation method thereof | |
| María et al. | Neurobehavioral and toxicological effects of an aqueous extract of Turnera diffusa Willd (Turneraceae) in mice | |
| Hosseini | Therapeutic effects of medicinal herbs on reproductive system disorders: a review | |
| Purnamasari et al. | The effectiveness of zinc micronutrients from pumpkin (Cucurbita moschata D) extract on the testosterone levels of mice (Mus musculus L) | |
| Al-Ani et al. | Protective role of eurycoma longifolia jack root extract against high-fat diet induced testicular damage in sprague-dawley rats | |
| CN104644698B (en) | A kind of product for preventing senile dementia and preparation method thereof | |
| EP3750532A1 (en) | A food supplement for use in restoring male sex drive (libido) | |
| Arini | The study of sex steroid hormone compound in green algae (Chlorophyta) for female fertility: A literature review | |
| KR20000002474A (en) | Preventive and therapeutic agent for degenerative cerebrum neurological disease | |
| Kumar et al. | Therapeutic Effect of Herbal Medicinal Plants on Polycystic Ovarian Syndrome: A Review | |
| Chandru et al. | Effect of raw extract of Clitoria ternatea L. on sexual stimulate test of female genital tract in rat | |
| KR20110089036A (en) | Functional food composition for treating infetility | |
| Ahmad et al. | Effect of Hydromethanolic Fruit Pulp Extract of Azanza garckeana (Malvaceae) on Sexual Behavior, Sex Hormones and Histology of Female Wistar Rats | |
| Okwute et al. | Evaluation of Abrus precatorius on reproductive function of male Wistar rat | |
| Han et al. | Effect and mechanism of pearl on ovarian function of rats with premature ovarian failure induced by tripterygium glycosides | |
| Takara et al. | Moriche Palm (Aguaje) Extract improves indefinite complaints in Japanese females: a randomized, placebo-controlled, double-blind trial | |
| RU2473358C1 (en) | Composition possessing adaptogenic, hepatoprotective and immunomodulatory action | |
| Cemali et al. | Female infertility and the Mediterranean Diet |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160921 |
|
| RJ01 | Rejection of invention patent application after publication |